Document is current
Any future updates will be listed below
-
Authors
Klöbl, Manfred https://orcid.org/0000-0003-2107-8803
Murgaš, Matej https://orcid.org/0000-0001-7643-2182
Reed, Murray Bruce
Silberbauer, Leo Robert https://orcid.org/0000-0002-8521-1012
Hartmann, Annette M.
Godbersen, Godber Mathis https://orcid.org/0000-0002-9739-0724
Gryglewski, Gregor https://orcid.org/0000-0002-7344-8071
Nics, Lukas
Hahn, Andreas https://orcid.org/0000-0001-9727-7580
Rujescu, Dan https://orcid.org/0000-0002-1432-313X
Hacker, Marcus https://orcid.org/0000-0002-4222-4083
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
-
Funding
Funding for this research was provided by:
Austrian Science Fund (https://doi.org/10.55776/KLI1006, https://doi.org/10.55776/DOC33)
Vienna Science and Technology Fund (https://doi.org/10.47379/CS18039)
Österreichischen Akademie der Wissenschaften (DOC, DOC, DOC)
- License Information
-
More Information
Article History
Received: 6 September 2024
Revised: 5 May 2025
Accepted: 21 May 2025
First Online: 11 June 2025
Ethics approval and consent to participate
: The study was approved by the ethics committee of the Medical University of Vienna (number 1307/2014). All Procedures were performed according to the Declaration of Helsinki and the good scientific practice guidelines of the Medical University of Vienna. Written informed consent was obtained from all participants.
: R. Lanzenberger received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR and travel grants and/or conference speaker honoraria from Janssen-Cilag Pharma GmbH in 2023, and Bruker BioSpin, Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, Heel and Roche Austria GmbH., and Janssen-Cilag Pharma GmbH in the years before 2020. He is a shareholder of the start-up company BM Health GmbH, Austria since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. D. Rujescu served as consultant for Boehringer-Ingelheim and Janssen, received honoraria from Boehringer-Ingelheim, Gerot Lannacher, Indorsia, Janssen and Pharmagenetix, received research/ travel support from Angelini, Boehringer-Ingelheim, Janssen and Schwabe, and served on advisory boards of AC Immune, Boehringer-Ingelheim, Indorsia, Roche and Rovi. The remaining authors declare no potential conflict of interest with respect to the research, authorship, and/ or publication of this article.
